Pulmonary Arterial Hypertension: Navigating the Treatment Paradigm, Emerging Therapies, and Health Care System Impact

Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the latest guidelines and recommendations for the treatment of pulmonary arterial hypertension (PAH) and how they differ from previous versions.

A cardiovascular specialist provides an overview of emerging therapies and targets in the PAH treatment space and how they address current unmet needs.

Ioana Preston, MD, discusses unmet needs in the management of pulmonary arterial hypertension (PAH) and the challenges associated with the progressive nature of the disease.

An expert on pulmonary arterial hypertension discusses the limitations of current therapies and the barriers to early diagnosis.

Marius Hoeper, MD, discusses the direct medical costs and indirect socioeconomic costs associated with the treatment of pulmonary arterial hypertension (PAH), including hospitalizations, outpatient care, and patient productivity and quality of life.

An expert on pulmonary arterial hypertension discusses the potential impact of emerging therapies, including sotatercept, ralinepag, and inhaled imatinib.

Dr Oudiz discusses clinical data that support the efficacy and safety of emerging PAH therapies and ongoing research in the treatment space.

An expert on pulmonary arterial hypertension discusses how sotatercept might fit into current treatment paradigms and key factors that should guide clinical decision-making.

Focusing on the complexity of PAH management, Ioana Preston, MD, discusses the importance of combination therapies, close monitoring, and provides insight on counseling patients through treatment.

Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.

Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the challenges and limitations associated with the adoption of new treatments and the impact of emerging therapies on patient outcomes, quality of life, and disease management in the long term.

Ioana Preston, MD, highlights treatment considerations for managing PAH in specific patient populations and discusses the unmet needs that can be addressed by novel therapeutic approaches or improved treatment strategies.

Following a review of strategies and care delivery models that could help optimize the management of PAH, Marius Hoeper, MD, discusses his recent publication on the long-term impact of sotatercept on morbidity and mortality.

Marius Hoeper, MD, describes the role clinicians can play in advocating for health care system reforms that could address the economic implications of PAH and discusses the key unmet needs in the PAH treatment landscape.